Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN) https://www.acasti.com/en/investors/news-events/press-releases/detail/239/acasti-pharma-announces-preliminary-topline-results-met-all